Jedd D. Wolchok, MD, PhD (Damon Runyon-Lilly Clinical Investigator ‘03-‘08) and colleagues at Memorial Sloan Kettering Cancer Center, New York, reported the results of a Phase I study testing a combination therapy (Yervoy plus Opdivo/nivolumab) vs. Yervoy alone in patients with metastatic melanoma (with wild type BRAF gene). In 72 patients, the rate of confirmed response was 61% for the combination therapy (22% with complete response) vs. 11% for Yervoy alone (0% complete response). These results were published in the journal The New England Journal of Medicine.
